Results

1–8 of 8 results for NPDR

Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Amine Oxidase Copper-Containing 3 Inhibitor (BI 1467335) in Non-Proliferative Diabetic Retinopathy: Double-Masked, Randomized, Phase IIa Study (ROBIN)
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2021
Treatment Effect of Intravitreal Aflibercept Injection by Baseline Factors in Moderately Severe-to-Severe NPDR in PANORAMA
Nathan C. Steinle, MD
Annual Meeting Talks
2020
Progression to Proliferative Diabetic Retinopathy in Nonproliferative Diabetic Retinopathy Eyes Without Diabetic Macular Edema in the United States
Ehsan Rahimy, MD
Annual Meeting Talks
2020
Intravitreal Aflibercept Injection for Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Study
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2020
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): The Phase 3 PANORAMA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2018